Abstract
Dopamine (DA) replacement therapy continues to be the gold standard treatment for Parkinson's disease (PD), as it improves key motor symptoms including bradykinesia and gait disturbances. With time, treatment induces side effects in the majority of patients, known as L-DOPA-induced dyskinesia (LID), which are often studied in animals by the use of unilateral, toxin-induced rodent models. In this study, we used the progressive, genetic PD model MitoPark to specifically evaluate bilateral changes in motor behavior following long-term L-DOPA treatment at three different stages of striatal DA depletion. Besides locomotor activity, we assessed changes in gait with two automated gait analysis systems and the development of dyskinetic behavior. Long-term treatment with a moderate, clinically relevant dose of L-DOPA (8 mg/kg) gradually produced age-dependent hyperactivity in MitoPark mice. In voluntary and forced gait analyses, we show that MitoPark mice with severe DA depletion have distinct gait characteristics, which are normalized to control levels following long-term L-DOPA treatment. The cylinder test showed an age-dependent and gradual development of bilateral LID. Significant increase in striatal FosB and prodynorphin expressio...Continue Reading
References
May 1, 1991·Journal of the Neurological Sciences·O BlinG Serratrice
Jun 1, 1991·Clinical Neuropharmacology·C W OlanowD Bush
Oct 10, 1998·The European Journal of Neuroscience·M A CenciA Björklund
Dec 22, 1999·Neurobiology of Disease·M AnderssonM A Cenci
Jun 23, 2004·Neurobiology of Disease·M LundbladM A Cenci
Feb 25, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Dong-Youn HwangKwang-Soo Kim
Jul 27, 2005·Journal of Neuroengineering and Rehabilitation·Ivo AmendeThomas G Hampton
Sep 6, 2005·Biological Psychiatry·Nancy PavónRosario Moratalla
Jan 18, 2007·Proceedings of the National Academy of Sciences of the United States of America·Mats I EkstrandNils-Göran Larsson
May 15, 2007·Neurobiology of Disease·Yunmin DingUn Jung Kang
Feb 19, 2008·The FEBS Journal·Mügen Terzioglu, Dagmar Galter
Sep 16, 2008·Molecular and Cellular Neurosciences·Marie WesterlundDagmar Galter
Nov 5, 2008·Journal of Motor Behavior·Thomas S GuillotGary W Miller
Nov 13, 2009·Journal of Motor Behavior·Thomas G Hampton, Ivo Amende
Dec 17, 2009·Genes, Brain, and Behavior·D GalterL Olson
Jan 30, 2010·Parkinsonism & Related Disorders·Mats I Ekstrand, Dagmar Galter
Feb 16, 2010·Journal of Biomedical Science·Chieh-Sen ChuangChin-San Liu
Oct 5, 2010·Progress in Brain Research·Susan H Fox, Jonathan M Brotchie
Dec 29, 2010·Proceedings of the National Academy of Sciences of the United States of America·Yunmin DingUn Jung Kang
Oct 20, 2011·Behavioural Brain Research·J E WestinY Temel
Aug 30, 2012·Nature Methods·Caroline A SchneiderKevin W Eliceiri
Jan 31, 2013·Experimental Neurology·Nicolas MorinThérèse Di Paolo
Jun 19, 2013·Biological Psychiatry·Luz M SuárezRosario Moratalla
Jan 1, 2011·Journal of Parkinson's Disease·Sébastien LopezGilberto Fisone
Oct 4, 2013·EJNMMI Research·Matthew D WalkerVesna Sossi
Oct 22, 2013·Neurobiology of Disease·Ramiro González-Aparicio, Rosario Moratalla
Citations
Sep 5, 2015·International Journal of Molecular Sciences·Yu LuoXin Qi
Mar 10, 2016·Experimental Gerontology·Li WangGeming Shi
Sep 13, 2015·Behavioural Brain Research·Ria de HaasJan A Smeitink
Jun 19, 2015·Brain Research·Lufei ShanCristina M Bäckman
Oct 30, 2016·Brain Research·Ariana Q FarrandHeather A Boger
Jan 11, 2017·Cephalalgia : an International Journal of Headache·Thomas List, Rigmor Højland Jensen
Jul 28, 2019·Sensors·Waseem Abbas, David Masip Rodo
Nov 15, 2020·Progress in Neurobiology·Tengfei WanGabriele C Saretzki
Sep 23, 2021·ELife·Gha-Hyun J KimSu Guo